Stan Berenshteyn
Stock Analyst at Wells Fargo
(1.00)
# 1,550
Out of 4,496 analysts
49
Total ratings
40%
Success rate
-10.13%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DOCS Doximity | Downgrades: Underweight | $27 → $19 | $28.22 | -32.67% | 7 | Jul 18, 2024 | |
| HQY HealthEquity | Maintains: Overweight | $107 → $110 | $73.38 | +49.90% | 8 | Jun 20, 2024 | |
| HCAT Health Catalyst | Maintains: Overweight | $14 → $13 | $7.26 | +79.06% | 4 | May 10, 2024 | |
| ACCD Accolade | Maintains: Equal-Weight | $12 → $10 | $3.45 | +189.86% | 9 | Apr 30, 2024 | |
| GDRX GoodRx Holdings | Upgrades: Overweight | $10 | $8.50 | +17.65% | 6 | Mar 25, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $28 → $26 | $27.52 | -5.52% | 9 | Feb 9, 2024 | |
| VEEV Veeva Systems | Upgrades: Overweight | $211 → $229 | $183.25 | +24.97% | 3 | Oct 25, 2023 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $28 → $23 | $9.09 | +153.03% | 2 | Mar 6, 2023 | |
| AMWL American Well | Maintains: Equal-Weight | $120 → $80 | $7.77 | +929.60% | 1 | Feb 28, 2022 |
Doximity
Jul 18, 2024
Downgrades: Underweight
Price Target: $27 → $19
Current: $28.22
Upside: -32.67%
HealthEquity
Jun 20, 2024
Maintains: Overweight
Price Target: $107 → $110
Current: $73.38
Upside: +49.90%
Health Catalyst
May 10, 2024
Maintains: Overweight
Price Target: $14 → $13
Current: $7.26
Upside: +79.06%
Accolade
Apr 30, 2024
Maintains: Equal-Weight
Price Target: $12 → $10
Current: $3.45
Upside: +189.86%
GoodRx Holdings
Mar 25, 2024
Upgrades: Overweight
Price Target: $10
Current: $8.50
Upside: +17.65%
Omnicell
Feb 9, 2024
Maintains: Equal-Weight
Price Target: $28 → $26
Current: $27.52
Upside: -5.52%
Veeva Systems
Oct 25, 2023
Upgrades: Overweight
Price Target: $211 → $229
Current: $183.25
Upside: +24.97%
Teladoc Health
Mar 6, 2023
Maintains: Equal-Weight
Price Target: $28 → $23
Current: $9.09
Upside: +153.03%
American Well
Feb 28, 2022
Maintains: Equal-Weight
Price Target: $120 → $80
Current: $7.77
Upside: +929.60%